{"id":11770,"date":"2026-10-30T18:25:29","date_gmt":"2026-10-30T15:25:29","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?page_id=11770"},"modified":"2026-10-30T18:25:29","modified_gmt":"2026-10-30T15:25:29","slug":"prucalopride-english","status":"publish","type":"page","link":"https:\/\/www.ortaakarsu.net\/?page_id=11770","title":{"rendered":"Prucalopride: Uses, Safety and Drug Interactions"},"content":{"rendered":"

Prucalopride: uses, safety and drug interactions<\/h2>\n

Overview:<\/strong> Prucalopride is a selective serotonin-4 receptor agonist that stimulates intestinal propulsive activity. The UK product information reviewed here concerns chronic constipation in adults whose laxatives have not provided adequate relief. It is an oral film-coated tablet, not an emergency treatment for possible bowel obstruction and not a general remedy for every cause of abdominal pain.<\/p>\n

Uses and formulation:<\/strong> The tablet may be taken with or without food. Kidney function, liver disease and age can influence the prescribing plan. A clinician should reassess a lack of benefit and review longer-term treatment periodically. The UK label contraindicates use in dialysis-dependent renal impairment, bowel perforation or obstruction, and specified severe inflammatory bowel conditions. Do not increase the prescribed amount because symptoms persist.<\/p>\n

Safety:<\/strong> Headache, nausea, abdominal pain and diarrhoea are frequent early adverse effects. Dizziness or tiredness can affect activities requiring alertness. Severe diarrhoea, dehydration, rectal bleeding or concerning abdominal pain needs assessment. The US FDA label additionally warns about new or worsening depression, suicidal thoughts and unusual behavioural changes; a causal relationship has not been established, but these symptoms require immediate contact with a healthcare professional. Pregnancy is not recommended under the UK label, and breastfeeding requires individual benefit-risk review.<\/p>\n

Drug interactions:<\/strong> Prucalopride has relatively low metabolic interaction potential. Studies found no clinically relevant pharmacokinetic effect on several medicines, including warfarin and digoxin; this does not remove their usual monitoring requirements. Strong P-glycoprotein inhibitors may modestly increase prucalopride exposure. Severe diarrhoea can reduce the reliability of oral contraception, so follow the contraceptive product instructions and obtain professional advice about additional protection.<\/p>\n

Sources<\/h2>\n